%0 Journal Article
%T Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept
%A Mayte Su¨˘rez-Fari£żas
%A Kejal R Shah
%A Asifa S Haider
%A James G Krueger
%A Michelle A Lowes
%J BMC Dermatology
%D 2010
%I BioMed Central
%R 10.1186/1471-5945-10-1
%X Microarray data from PBMCs of 16 of these patients was analyzed to generate a treatment response classifier. We used a discriminant analysis method that performs sample classification from gene expression data, via "nearest shrunken centroid method". Centroids are the average gene expression for each gene in each class divided by the within-class standard deviation for that gene.A disease response classifier using 23 genes was created to accurately predict response to alefacept (12.3% error rate). While the genes in this classifier should be considered as a group, some of the individual genes are of great interest, for example, cAMP response element modulator (CREM), v-MAF avian musculoaponeurotic fibrosarcoma oncogene family (MAFF), chloride intracellular channel protein 1 (CLIC1, also called NCC27), NLR family, pyrin domain-containing 1 (NLRP1), and CCL5 (chemokine, cc motif, ligand 5, also called regulated upon activation, normally T expressed, and presumably secreted/RANTES).Although this study is small, and based on analysis of existing microarray data, we demonstrate that a treatment response classifier for alefacept can be created using gene expression of PBMCs in psoriasis. This preliminary study may provide a useful tool to predict response of psoriatic patients to alefacept.Developing biomarkers that predict response to therapy is an ambitious goal of modern medicine. This is an aspect of personalized medicine that could transform our ability to treat patients successfully with a particular therapy in a cost-effective manner. Alefacept, an anti-CD2 fusion protein (Amevive, Astellas Pharma), is a biologic agent that often induces a remarkably durable remission [1]. However, it produces a PASI 75 response (Psoriasis Area and Severity Index [PASI] response of greater than 75% improvement from baseline) in only approximately 30-50% of patients. Thus alefacept is an excellent example of a treatment that would benefit from being able to predict which patients wi
%U http://www.biomedcentral.com/1471-5945/10/1